On January 30, Gelonghui Pharmaceutical (002581.SZ) announced that it expects a net loss of 243.39 million yuan to 345.09 million yuan in 2023, after deducting non-net loss of 228.87 million yuan to 330.57 million yuan.

According to corporate accounting standards and relevant accounting policy regulations, some long-term assets of the company were tested for impairment based on comprehensive influencing factors such as the company's actual operating conditions, changes in the industry market, and asset operation. The initial judgment was that there may be signs of impairment. According to the company's preliminary estimates, the company is expected to calculate impairment preparations for relevant long-term assets in the 2023 annual report: the impairment of fixed assets is expected to be 165 million yuan to 230 million yuan; the impairment of intangible assets is estimated at 30 million yuan to 38 million yuan; the impairment of other assets is estimated at 77 million yuan to 10 million yuan, and the total asset impairment is expected to be 272 million yuan to 368 million yuan. The final amount of impairment will be determined by the evaluation agency hired by the company and the company's annual auditor after evaluation and audit.